ARS Pharmaceuticals, Inc. (SPRY) Debt Components
- 2026-06-30: Long-term DebtUSD $96.68M; Long-Term Debt, Maturity, Remainder of Fiscal YearUSD (m); Debt Instrument, Face AmountUSD $100.00M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $3.32M.
- 2026-03-31: Long-term DebtUSD $96.52M; Long-Term Debt, Maturity, Remainder of Fiscal YearUSD (m); Debt Instrument, Face AmountUSD $100.00M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $3.48M.
- 2025-12-31: Long-term DebtUSD $96.37M; Long-Term Debt, Maturity, Remainder of Fiscal YearUSD (m); Debt Instrument, Face AmountUSD $100.00M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $3.63M.
- 2025-09-30: Long-term DebtUSD $96.23M; Long-Term Debt, Maturity, Remainder of Fiscal YearUSD $300.00K; Debt Instrument, Face AmountUSD $100.00M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $3.77M.
ARS Pharmaceuticals, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Face Amount USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Notes Payable, Current USD |
|---|---|---|---|---|---|
| 2026-06-30 | $96.68M | (m) | $100.00M | $3.32M | (m) |
| 2026-03-31 | $96.52M | (m) | $100.00M | $3.48M | (m) |
| 2025-12-31 | $96.37M | (m) | $100.00M | $3.63M | (m) |
| 2025-09-30 | $96.23M | $300.00K | $100.00M | $3.77M | (m) |
| 2025-06-30 | (m) | $310.00K | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | $0.00 |
| 2021-12-31 | (m) | (m) | (m) | (m) | $3.48M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |